Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.943
Neutral
RSI(14)
24.776
Sell
STOCH(KDJ)(9,3,3)
36.155
Sell
ATR(14)
2.558
High Vlolatility
CCI(14)
-466.667
Oversold
Williams %R
97.601
Oversold
TRIX(12,20)
-0.133
Sell
StochRSI(14)
0.000
Sell
Search
BIOAGE Labs Inc
BIOAAdd to Watchlist
9.040USD
-15.810-63.62%
Close 07-31 16:00（ET）Quotes delayed by 15 min
401.85MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-63.62%
5 Days
-58.47%
1 Month
-63.98%
6 Months
-55.02%
Year to Date
-31.67%
1 Year
+119.42%
Key Figures
8.770Open
10.810High
9.98MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
22.48%Turnover Ratio
24.850Prev. Close
8.650Low
67.98MTurnover
LossP/E Static
1.06P/B
0.00%Div Yield TTM
-24.26%ROA
24.00052wk High
3.90Volume Ratio
-71.11MNet Profit
44.39MShares
-2.4064EPS TTM
--Beta
-25.98%ROE
3.88052wk Low
8.69%Amplitude
100.00%Gross Margin
401.85MMarket Cap
0.01Reward/Risk
4.55%Risk Rate
TradingKey Stock Score of BIOAGE Labs Inc
Currency: USD Updated: 2026-07-31Key Insights
BIOAGE Labs Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 52 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 42.88.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BIOAGE Labs Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BIOAGE Labs Inc Highlights
StrengthsRisks
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.99M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.99M.
Fairly Valued
The company’s latest PE is -3.76, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.69M shares, decreasing 9.72% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 193.51K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
42.875
Target Price
+374.28%
Upside Space
BIOAGE Labs Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
42.875
Target Price
+374.28%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
BIOAGE Labs Inc
BIOA
9
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
19.776
Sell
MA10
20.946
Sell
MA20
22.190
Sell
MA50
20.349
Sell
MA100
19.122
Sell
MA200
16.523
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BIOAGE Labs Inc Info
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Ticker SymbolBIOA
CompanyBIOAGE Labs Inc
CEOFortney (Kristen)
Websitehttps://bioagelabs.com
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52758.700
+380.700 (+0.73%)
28493.900
+333.000 (+1.18%)
7531.000
+55.900 (+0.75%)
14593.000
-156.000 (-1.06%)
63763.000
+911.000 (+1.45%)
6398.800
+33.400 (+0.53%)
78.130
-7.804 (-9.08%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4065.220
+23.790 (+0.59%)
FAQs
What is the current price of BIOAGE Labs Inc (BIOA)?
The current price of BIOAGE Labs Inc (BIOA) is 9.04.
What is the symbol of BIOAGE Labs Inc?
The ticker symbol of BIOAGE Labs Inc is BIOA.
What is the 52-week high of BIOAGE Labs Inc?
The 52-week high of BIOAGE Labs Inc is 24.00.
What is the 52-week low of BIOAGE Labs Inc?
The 52-week low of BIOAGE Labs Inc is 3.88.
What is the market capitalization of BIOAGE Labs Inc?
The market capitalization of BIOAGE Labs Inc is 401.85M.
Is BIOAGE Labs Inc (BIOA) currently rated as Buy, Hold, or Sell?
According to analysts, BIOAGE Labs Inc (BIOA) has an overall rating of Buy, with a price target of 42.88.
What is the Earnings Per Share (EPS TTM) of BIOAGE Labs Inc (BIOA)?
The Earnings Per Share (EPS TTM) of BIOAGE Labs Inc (BIOA) is -2.24.